0.42

1.82% +0.0075

After Hours: .42

GRI Bio Inc (GRI)

Overview News Price History Discussions Forecast

GRI Bio Inc stock is currently priced at $0.42, with a 24-hour trading volume of 254.52K. It has seen a +1.82% increased in the last 24 hours and a -17.65% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.4158 pivot point. If it approaches the $0.4267 resistance level, significant changes may occur.

Previous Close:

$0.4125

Open:

$0.4519

24h Volume:

254.52K

Market Cap:

$1.59M

Revenue:

Net Income/Loss:

$-13.28M

P/E Ratio:

-0.0915

EPS:

-4.5911

Net Cash Flow:

$-8.99M

1W Performance:

+2.44%

1M Performance:

-17.65%

6M Performance:

-61.33%

1Y Performance:

-92.67%

1D Range:

$0.413

$0.4519

52W Range:

$0.2505

$7.04

GRI Bio Inc Stock (GRI) Company Profile

Name

GRI Bio Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

619 400 1171

Address

2223 Avenida DE LA Playa, Suite 208, La Jolla

Employee

Twitter

Next Earnings Date

2024-06-07

Latest SEC Filings

GRI's Discussions on Twitter

GRI Bio Inc Stock (GRI) Latest News

GRI Bio (NASDAQ:GRI) Shares Down 1.2% - Defense World

Defense World

Coveo Solutions Inc. (TSE:CVO) Given Average Rating of “Buy” by Brokerages - Defense World

Defense World

EVgo (NYSE:EVGO) Sees Unusually-High Trading Volume Following Insider Buying Activity - Defense World

Defense World

Analysts Set Expectations for AAON, Inc.'s Q4 2024 Earnings (NASDAQ:AAON) - Defense World

Defense World

Brokers Set Expectations for Aethlon Medical, Inc.'s FY2024 Earnings (NASDAQ:AEMD) - Defense World

Defense World

Primary Sclerosing Cholangitis Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies ... - openPR

openPR

GRI Bio Inc Stock (GRI) Financials Data

GRI Bio Inc (GRI) Net Income 2024

GRI net income (TTM) was -$13.28 million for the quarter ending December 31, 2023, a -139.33% decrease year-over-year.

GRI Bio Inc (GRI) Cash Flow 2024

GRI recorded a free cash flow (TTM) of -$8.99 million for the quarter ending December 31, 2023, a -728.57% decrease year-over-year.

GRI Bio Inc (GRI) Earnings per Share 2024

GRI earnings per share (TTM) was -$30.28 for the quarter ending December 31, 2023, a -130.49% decline year-over-year.

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.